Domain Therapeutics

Activities: Research & Development Pharmaceutical

Trending Articles

  1. OINDPs: Nosey about recent developments? OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
  2. Transforming healthcare with patient centricity In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Compact process thermostat for efficient temperature control in the laboratory The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
  5. AviadoBio expands presence at Canary Wharf The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Ingredients

Domain makes two acquisitions for G Protein-Coupled Receptor programme

Prestwick Chemical and Neurofit are former subsidiaries of Australia-based Bionomics
Research & Development

Domain Therapeutics adds Sylvie Ryckebusch to Board

Ryckebusch joins Domain from Merck Serono
Media

Domain Therapeutics receives $125m to assign its intellectual property

Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by a French biotech
Research & Development

Domain Therapeutics and Pfizer collaborate on bioSensAll

Technology will be used to profile signaling of mutant GPCRs to accelerate validation of novel GPCR drug targets
Finance

Merck will develop Domain Therapeutics next generation adenosine receptor programs

Domain Therapeutics and Merck enter into an agreement for development of adenosine receptor antagonists in immuno-oncology
Research & Development

Domain Therapeutics closes €2m funding round

Will use money to strengthen partnerships for discovering drugs targeting GPCRs
Research & Development

Domain Therapeutics wins €933,000 grant for schizophrenia project

French GPCR specialist will lead €5.1m ATHOS project
Subscribe now